Valneva Execs to Present at Key Conferences Amid Lyme Vaccine Data Watch
Event summary
- Valneva CEO Thomas Lingelbach and CFO Peter Buhler to present at three investor conferences in March and April 2026.
- Key focus: topline Phase 3 data readout for Lyme disease vaccine candidate VLA15, with Pfizer expected to report in H1 2026.
- TD Cowen presentation on March 4 to be webcast live and available for replay.
- Investor meetings scheduled at Jefferies Biotech on the Beach Summit (March 10) and Van Lanschot Kempen Life Sciences Conference (April 15).
The big picture
Valneva's participation in high-profile investor conferences underscores the strategic importance of its Lyme disease vaccine candidate, VLA15, which is partnered with Pfizer. The upcoming Phase 3 data readout could significantly influence Valneva's market trajectory, particularly as it competes in a sector characterized by high R&D costs and regulatory scrutiny. The company's ability to balance commercial success with pipeline advancement will be critical in maintaining investor confidence.
What we're watching
- Clinical Milestones
- How the Phase 3 data readout for VLA15 will impact Valneva's partnership with Pfizer and market positioning.
- Investor Sentiment
- Whether Valneva can sustain investor interest amid competitive pressures in the vaccine sector.
- Commercial Strategy
- The pace at which Valneva advances its pipeline while maintaining revenue growth from existing travel vaccines.
Related topics